- Home
- Publications
- Publication Search
- Publication Details
Title
Atacicept: targeting B cells in multiple sclerosis
Authors
Keywords
-
Journal
Therapeutic Advances in Neurological Disorders
Volume 3, Issue 4, Pages 205-216
Publisher
SAGE Publications
Online
2010-06-10
DOI
10.1177/1756285610371146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL
- (2014) M. J. Benson et al. JOURNAL OF IMMUNOLOGY
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- Environmental factors and their timing in adult-onset multiple sclerosis
- (2010) Adam E. Handel et al. Nature Reviews Neurology
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis
- (2009) Olaf Stüve et al. ARCHIVES OF NEUROLOGY
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
- (2009) Volker Brinkmann BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus
- (2009) I. Nestorov et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus
- (2009) C Pena-Rossi et al. LUPUS
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells
- (2008) Stamatis-Nick C. Liossis et al. CLINICAL IMMUNOLOGY
- B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data
- (2008) Kathleen Hawker CURRENT OPINION IN NEUROLOGY
- B lymphocytes - chief players and therapeutic targets in autoimmune diseases
- (2008) Moncef Zouali Frontiers in Bioscience-Landmark
- Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
- (2008) Ivan Nestorov et al. JOURNAL OF CLINICAL PHARMACOLOGY
- B cells and multiple sclerosis
- (2008) Diego Franciotta et al. LANCET NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept
- (2008) Michela Carbonatto et al. TOXICOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started